GALT vs GDTC

Galectin Therapeutics Inc. vs CytoMed Therapeutics Limited — Valuation Comparison 2026

GALT

Biotechnology
Galectin Therapeutics Inc.
Quality
3.7
out of 10
Value Trap
12
SAFE
Price
$2.57
Last close
Models
6/13
Active
VS

GDTC

Biotechnology
CytoMed Therapeutics Limited
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$1.14
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType GALT Fair ValueGALT Upside GDTC Fair ValueGDTC Upside
Bayesian DCF Intrinsic $0.80 -68.8% $0.32 -72.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.37 -67.1%
PWERM Option-Based $4.46 +73.5% $1.14 -0.4%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GALT vs GDTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GALT vs GDTC — Which Stock Is More Undervalued?

GDTC scores higher with a 5.1/10 quality rating vs GALT's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Galectin Therapeutics Inc. (GALT) and CytoMed Therapeutics Limited (GDTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GALT currently trades at $2.57 with a QOC of 3.7/10, while GDTC trades at $1.14 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).